利那洛肽联合聚乙二醇电解质散在肠道准备中的有效性及安全性meta分析  

Efficacy and safety of linaclotide combined with polyethylene glycol electrolyte powder in bowel preparation:A meta-analysis

作　　者：谢沁松 刘露路[1] 王珏[1] 郑艳[1] 古赛[1] XIE Qinsong;LIU Lulu;WANG Jue;ZHENG Yan;GU Sai(Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院消化内科,重庆400016

出　　处：《现代医药卫生》2023年第23期4051-4056,共6页Journal of Modern Medicine & Health

摘　　要：目的 系统评价利那洛肽联合聚乙二醇(PEG)电解质散在肠道准备中的有效性和安全性。方法 计算机检索PubMed、Web of Science、the Cochrane Library、Embase、中国知网、中国生物医学文献数据库、万方、维普网数据库,搜集有关利那洛肽联合PEG作为肠道准备方案的临床研究,检索时间均从建库起至2023年5月。由2位研究者独立对纳入文献进行资料提取和质量评价,使用RevMan5.4软件进行meta分析。结果 最终共纳入11篇文献,共计2 381例患者,其中利那洛肽联合PEG组1 193例,PEG组1 188例。Meta分析结果显示,利那洛肽联合PEG组波士顿肠道准备评分[平均差(MD)=-0.02,95%可信区间(95%CI)-0.10~0.07,P=0.69]、腺瘤检出率[相对危险度(RR)=0.95,95%CI 0.78~1.16,P=0.61]与PEG组相比无显著差异。在安全性方面,利那洛肽联合PEG组恶心发生率(RR=0.48,95%CI 0.39~0.58,P<0.001)、腹胀发生率(RR=0.46,95%CI 0.33~0.63,P<0.001)、腹痛发生率(RR=0.27,95%CI 0.16~0.43,P<0.001)、呕吐发生率(RR=0.32,95%CI 0.19~0.52,P<0.001)均显著低于PEG组。结论 利那洛肽联合PEG作为肠道准备方案不仅可减少PEG的用量,还可减少胃肠道不良反应的发生。Objective To systematically evaluate the efficacy and safety of linaclotide combined with polyethylene glycol(PEG)electrolyte powder in bowel preparation.Methods PubMed,Web of Science,the Cochrane Library,Embase,China National Knowledge Infrastructure(CNKI),China Biomedical Literature Database(CBM),Wanfang and VIP databases were searched by computer to collect clinical studies on linaclotide combined with PEG as a bowel preparation regimen.The search time was from the establishment of the databases to May 2023.Two researchers independently extracted data and assessed the quality of the included studies.Meta-analysis was performed using RveMan5.4 software.Results A total of 11 articles were included,with a total of 2381 patients,including 1193 cases in the linaclotide combined with PEG group and 1188 cases in the PEG group.The results of meta-analysis showed that there was no significant difference in Boston bowel preparation score[mean difference(MD)=-0.02,95%confidence interval(95%CI)-0.10-0.07,P=0.69]and adenoma detection rate[relative risk(RR)=0.95,95%CI 0.78-1.16,P=0.61]between linaclotide combined with PEG group and PEG group.In terms of safety,the incidence of nausea(RR=0.48,95%CI 0.39-0.58,P<0.001),abdominal distension(RR=0.46,95%CI 0.33-0.63,P<0.001),abdominal pain(RR=0.27,95%CI 0.16-0.43,P<0.001)and vomiting(RR=0.32,95%CI 0.19-0.52,P<0.001)in the linaclotide combined with PEG group were significantly lower than those in the PEG group.Conclusion As a bowel preparation regimen,linaclotide combined with PEG can not only reduce the amount of PEG,but also reduce the incidence of gastrointestinal adverse reactions.

关 键 词：利那洛肽 肠道准备 META分析 有效性 安全性 

分 类 号：R659[医药卫生—外科学]